Feasibility Pilot for the ReBOO-trial (ReBOO)
Primary Purpose
Obesity
Status
Completed
Phase
Phase 2
Locations
Norway
Study Type
Interventional
Intervention
Intragastric botulinum toxin type A
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring Adolescent, Injections, intraperitoneal, Endoscopy, Botulinum Toxins, Type A, OnabotulinumtoxinA
Eligibility Criteria
Inclusion Criteria:
- Written (signed) informed consent
- Age and gender adjusted body mass index (ISO-BMI) ≥ 35 or ISO-BMI > 30 with comorbidities including hypertension, non-alcoholic fatty liver disease, hyperlipidemia or impaired glucose tolerance
- Having partaken in a comprehensive multi-disciplinary lifestyle treatment for obesity of duration 12 months or more, without achieving a clinically significant weight loss (non-responder)
Exclusion Criteria:
- Known hypersensitivity to excipients in the investigational medicine product (IMP)
- Neuromuscular disorders
- History of dysphagia
- History of aspiration tendency or aspiration pneumonia
- Known lung disease under continuous treatment
- Congenital or acquired heart disease
- Previous experience of side effects to Botulinum toxin type A
- Present gastric diseases or dysfunction
- Previous bariatric surgery
- History of cancer
- Serious binge eating disorder
- Untreated hypothyroidism
- Use of aminoglycoside antibiotics or spectinomycin in the week prior to injection, or any other medicinal product that interfere with neuromuscular transmission (neuromuscular blocking agents)
- Medication known to affect appetite
- Syndromic obesity
- Mentally immature to a degree that there is doubt about the subject's ability to assent
- Issues relating to language or culture that may complicate trial participation
- Pregnancy or breastfeeding
Sites / Locations
- St Olavs Hospital Trondheim University Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intragastric botulinum toxin type A
Arm Description
Botulinum toxin A (Allergan) injected intragastrically in the antrum
Outcomes
Primary Outcome Measures
BMI
Proportion of participants reaching a reduction in BMI z-score equal to or more than 1
Secondary Outcome Measures
Injection interval
Patient reports will indicate the appropriate re-injection interval
Patient adherence to treatment
Qualitative data based on interviews with patients and next of kin.
Incidence of treatment-emergent adverse events
All adverse events (AE), serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR) will be evaluated
Full Information
NCT ID
NCT03079557
First Posted
February 26, 2017
Last Updated
September 21, 2020
Sponsor
St. Olavs Hospital
Collaborators
Norwegian University of Science and Technology
1. Study Identification
Unique Protocol Identification Number
NCT03079557
Brief Title
Feasibility Pilot for the ReBOO-trial
Acronym
ReBOO
Official Title
A Non-randomised, Open Feasibility Pilot for the 'REpurposing BOtulinum Toxin in Treatment of Obesity in Adolescents' (ReBOO) Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
March 14, 2017 (Actual)
Primary Completion Date
April 30, 2019 (Actual)
Study Completion Date
April 30, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St. Olavs Hospital
Collaborators
Norwegian University of Science and Technology
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a pilot testing the feasibility of the 'REpurposing BOtulinum Toxin in Treatment of Obesity in Adolescents' trial (ReBOO-trial). The full-scale ReBOO will further investigate safety and efficacy of intragastric injections of botulinum toxin A into the antrum area of the stomach. These injections will be repeated every six months.
The study sample will be adolescents with obesity who have not responded to standard conservative treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Adolescent, Injections, intraperitoneal, Endoscopy, Botulinum Toxins, Type A, OnabotulinumtoxinA
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intragastric botulinum toxin type A
Arm Type
Experimental
Arm Description
Botulinum toxin A (Allergan) injected intragastrically in the antrum
Intervention Type
Drug
Intervention Name(s)
Intragastric botulinum toxin type A
Other Intervention Name(s)
Allergan
Intervention Description
200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
Primary Outcome Measure Information:
Title
BMI
Description
Proportion of participants reaching a reduction in BMI z-score equal to or more than 1
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Injection interval
Description
Patient reports will indicate the appropriate re-injection interval
Time Frame
12 months
Title
Patient adherence to treatment
Description
Qualitative data based on interviews with patients and next of kin.
Time Frame
12 months
Title
Incidence of treatment-emergent adverse events
Description
All adverse events (AE), serious adverse events (SAE) and suspected unexpected serious adverse reactions (SUSAR) will be evaluated
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written (signed) informed consent
Age and gender adjusted body mass index (ISO-BMI) ≥ 35 or ISO-BMI > 30 with comorbidities including hypertension, non-alcoholic fatty liver disease, hyperlipidemia or impaired glucose tolerance
Having partaken in a comprehensive multi-disciplinary lifestyle treatment for obesity of duration 12 months or more, without achieving a clinically significant weight loss (non-responder)
Exclusion Criteria:
Known hypersensitivity to excipients in the investigational medicine product (IMP)
Neuromuscular disorders
History of dysphagia
History of aspiration tendency or aspiration pneumonia
Known lung disease under continuous treatment
Congenital or acquired heart disease
Previous experience of side effects to Botulinum toxin type A
Present gastric diseases or dysfunction
Previous bariatric surgery
History of cancer
Serious binge eating disorder
Untreated hypothyroidism
Use of aminoglycoside antibiotics or spectinomycin in the week prior to injection, or any other medicinal product that interfere with neuromuscular transmission (neuromuscular blocking agents)
Medication known to affect appetite
Syndromic obesity
Mentally immature to a degree that there is doubt about the subject's ability to assent
Issues relating to language or culture that may complicate trial participation
Pregnancy or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bård Eirik Kulseng, prof
Organizational Affiliation
Norwegian University of Science and Technology, Fac MH, IKOM
Official's Role
Study Director
Facility Information:
Facility Name
St Olavs Hospital Trondheim University Hospital
City
Trondheim
Country
Norway
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Feasibility Pilot for the ReBOO-trial
We'll reach out to this number within 24 hrs